1 |
Yates JL, Warren N and Sugden B (1985) Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313, 812-815
DOI
|
2 |
Kang MS, Hung SC and Kieff E (2001) Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. Proc Natl Acad Sci U S A 98, 15233-15238
DOI
|
3 |
Nasimuzzaman M, Kuroda M, Dohno S et al (2005) Eradication of epstein-barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1. Mol Ther 11, 578-590
DOI
|
4 |
Yin Q and Flemington EK (2006) siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology 346, 385-393
DOI
|
5 |
Miller JC, Tan S, Qiao G et al (2011) A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29, 143-148
DOI
|
6 |
Kim SY, Song KA, Kieff E and Kang MS (2012) Small molecule and peptide-mediated inhibition of Epstein-Barr virus nuclear antigen 1 dimerization. Biochem Biophys Res Commun 424, 251-256
DOI
|
7 |
Sung YH, Baek IJ, Kim DH et al (2013) Knockout mice created by TALEN-mediated gene targeting. Nat Biotechnol 31, 23-24
DOI
|
8 |
Lee EK, Kim SY, Noh KW et al (2014) Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome. Antiviral Res 104C, 73-83
DOI
|
9 |
Cohen JI, Mocarski ES, Raab-Traub N, Corey L and Nabel GJ (2013) The need and challenges for development of an Epstein-Barr virus vaccine. Vaccine 31 Suppl 2, B194-196
DOI
|
10 |
Kim Y, Kweon J, Kim A et al (2013) A library of TAL effector nucleases spanning the human genome. Nat Biotechnol 31, 251-258
DOI
|
11 |
Sung YH, Baek IJ, Seong JK, Kim JS and Lee HW (2012) Mouse genetics: catalogue and scissors. BMB Rep 45, 686-692
DOI
|
12 |
Molesworth SJ, Lake CM, Borza CM, Turk SM and Hutt-Fletcher LM (2000) Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells. J Virol 74, 6324-6332
DOI
|
13 |
Park J, Bae EK, Lee C et al (2014) Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-kappaB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis. BMB Rep 47, 274-279
DOI
|
14 |
Raynaud FI, Whittaker SR, Fischer PM et al (2005) In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 11, 4875-4887
DOI
|
15 |
Parkin DM (2006) The global health burden of infectionassociated cancers in the year 2002. Int J Cancer 118, 3030-3044
DOI
|
16 |
Granato M, Feederle R, Farina A et al (2008) Deletion of Epstein-Barr virus BFLF2 leads to impaired viral DNA packaging and primary egress as well as to the production of defective viral particles. J Virol 82, 4042-4051
DOI
|
17 |
Adams A and Lindahl T (1975) Epstein-Barr virus genomes with properties of circular DNA molecules in carrier cells. Proc Natl Acad Sci U S A 72, 1477-1481
DOI
|
18 |
Henderson A, Ripley S, Heller M and Kieff E (1983) Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro. Proc Natl Acad Sci U S A 80, 1987-1991
DOI
|
19 |
Kang MS, Lee EK, Soni V et al (2011) Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenance. J Virol 85, 2859-2868
DOI
|
20 |
Matsuo T, Heller M, Petti L, O'Shiro E and Kieff E (1984) Persistence of the entire Epstein-Barr virus genome integrated into human lymphocyte DNA. Science 226, 1322-1325
DOI
|
21 |
Sugden B, Marsh K and Yates J (1985) A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. Mol Cell Biol 5, 410-413
DOI
|